Glucose-dependent Insulinotropic Polypeptide (GIP)
Sponsors
Washington University School of Medicine, University of Copenhagen, Asger Lund, MD, Esbjerg Hospital - University Hospital of Southern Denmark, Novo Nordisk A/S
Conditions
Bone Disease, MetabolicDiabetesDiabetes Mellitus, Type 2EmesisHealthyObeseObesityObesity and Obesity-related Medical Conditions
Phase 1
Study of the Effects of Xenin-25 in Humans With and Without Type 2 Diabetes Mellitus
CompletedNCT00798915
Start: 2008-12-31End: 2012-12-31Updated: 2018-05-03
Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function
CompletedNCT00949663
Start: 2009-10-31End: 2014-02-28Updated: 2014-07-22
A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese
RecruitingNCT07411560
Start: 2026-02-09End: 2027-01-26Target: 100Updated: 2026-04-13
Unknown Phase
Effects of Gut Peptides on Bone Remodeling
CompletedNCT03574064
Start: 2018-06-01End: 2019-01-01Updated: 2021-01-20
The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes
CompletedNCT05078255
Start: 2022-01-27End: 2025-01-24Updated: 2025-03-14
Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA)
RecruitingNCT06790225
Start: 2025-11-10End: 2027-11-30Target: 12Updated: 2026-01-02
The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Subjects With and Without Type 1 Diabetes
CompletedNCT06881472
Start: 2025-01-01End: 2026-01-16Updated: 2026-04-29
The Antiemetic Effects of Increased Splanchnic Perfusion, Induced by the Gut Hormone GIP, in Healthy Individuals
Enrolling by invitationNCT07687589
Start: 2026-05-19End: 2027-04-28Target: 14Updated: 2026-07-07